High Growth Tech Stocks To Explore In November 2024

Over the last 7 days, the United States market has dropped 2.1%, yet it remains up 30% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks that align with these positive earnings forecasts can be a strategic approach for those looking to explore opportunities in November 2024.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Invivyd	54.76%	71.32%	★★★★★★
Sarepta Therapeutics	23.89%	42.65%	★★★★★★
Alkami Technology	21.89%	98.60%	★★★★★★
Alnylam Pharmaceuticals	22.45%	70.66%	★★★★★★
Clene	78.50%	60.70%	★★★★★★
TG Therapeutics	34.66%	56.48%	★★★★★★
Travere Therapeutics	31.75%	72.43%	★★★★★★
Blueprint Medicines	25.47%	68.62%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Ardelyx (NasdaqGM:ARDX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for gastrointestinal and cardiorenal therapeutic areas globally, with a market cap of approximately $1.18 billion.

Operations: Ardelyx operates in the biopharmaceutical sector, focusing on the development and commercialization of treatments for gastrointestinal and cardiorenal conditions. The company's revenue is primarily derived from its biopharmaceutical products, amounting to $251.85 million.

Ardelyx, Inc., a biotech firm specializing in novel treatments for kidney and cardiovascular diseases, has shown a notable uptick in revenue, with a 25.6% annual growth rate that surpasses the US market average of 8.9%. Despite currently being unprofitable, Ardelyx's strategic focus on R&D is evident from its recent clinical advancements with XPHOZAH®, a pioneering treatment for hyperphosphatemia in dialysis patients. This product differentiation emphasizes Ardelyx’s commitment to addressing unmet medical needs, which may bolster its financial trajectory as earnings are projected to surge by approximately 69.6% annually. Moreover, the company's recent filing for a $167.865 million shelf registration suggests plans for capitalizing on these innovations to potentially fuel further growth and profitability within the next three years.

• Click to explore a detailed breakdown of our findings in Ardelyx's health report.

• Examine Ardelyx's past performance report to understand how it has performed in the past.

National CineMedia (NasdaqGS:NCMI)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: National CineMedia, Inc. operates a cinema advertising network in North America through its subsidiary, National CineMedia, LLC, with a market cap of $629.29 million.

Operations: The company generates revenue primarily from advertising, with a reported $245.30 million in this segment.

National CineMedia's recent partnership with Comcast's Xfinity and others for the 4DX ad spot underscores its innovative approach in the advertising sector, enhancing cinema experience with technology-driven solutions. Despite a challenging financial backdrop marked by a significant net loss of $47 million over nine months and a downturn from last year’s profit of $681.5 million, the company is poised for recovery with projected earnings growth of 107% annually. This potential turnaround is further supported by an 11.8% annual revenue growth forecast, outpacing the US market average. The strategic collaborations and immersive advertising formats could redefine engagement metrics within the media landscape, setting a new standard for cinematic advertisements.

• Dive into the specifics of National CineMedia here with our thorough health report.

• Gain insights into National CineMedia's historical performance by reviewing our past performance report.

Reddit (NYSE:RDDT)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Reddit, Inc. operates a website that organizes digital communities with a market capitalization of $21.91 billion.

Operations: Reddit generates revenue primarily from its Internet Information Providers segment, amounting to $1.12 billion. The company's business model focuses on organizing digital communities, which serves as the backbone for its revenue streams.

Reddit's recent financial performance illustrates a significant turnaround, with third-quarter sales soaring to $348.35 million from $207.51 million year-over-year and net income reaching $29.85 million, reversing a previous loss of $7.38 million. This growth is underpinned by an aggressive R&D strategy, with expenses reflecting a commitment to innovation crucial for staying competitive in the tech sector. Looking ahead, Reddit anticipates Q4 revenues between $385 million and $400 million, signaling robust future prospects despite its current unprofitability and highly volatile share price over the past three months. This trajectory is supported by its inclusion in the S&P Global BMI Index, enhancing investor visibility and confidence in its strategic direction.

• Click here to discover the nuances of Reddit with our detailed analytical health report.

• Review our historical performance report to gain insights into Reddit's's past performance.

Taking Advantage

• Investigate our full lineup of 249 US High Growth Tech and AI Stocks right here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com